AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened

Posted by Donna Armstrong on Mar 16th, 2025

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £113.89 ($147.32) and traded as high as £120.20 ($155.48). AstraZeneca shares last traded at £119.94 ($155.14), with a volume of 1,437,588 shares.

Analyst Upgrades and Downgrades

AZN has been the topic of several research reports. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.81) price objective on shares of AstraZeneca in a research report on Monday, January 27th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday, March 7th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 7,542.80 ($97.57).

Get Our Latest Report on AZN

AstraZeneca Stock Up 0.9 %

The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock has a 50 day moving average price of £114.34 and a 200-day moving average price of £113.78. The stock has a market capitalization of £230.77 billion, a P/E ratio of 32.88, a PEG ratio of 0.86 and a beta of 0.17.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.